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Rice bran oil was extracted from rice bran collected after four milling breaks that were 
used to process rice in Bernas factory, Sekinchan, Malaysia. Two organic solvents were 
used, a non-polar solvent that was hexane and a mixture of non-polar and polar, which 
were chloroform-methanol. Gamma oryzanol content of rice bran oil was then 
quantified, and the total antioxidant activity (TAA) was determined using FTC and TBA 
methods. After oil extraction, dietary fiber content was quantified in the four phases of 
defatted rice bran. Results showed that rice bran contained around 20 % lipid in the 
extracts of the two solvents used. Unlike oil yield, y-oryzanol content was affected by 
rice milling and the type of solvent used for extraction. For chloroform-methanol 
extract, phase 2 of rice milling contained the highest amount of y-oryzanol (5280 * 120 
pprn), followed by phase 3 (3820 * 60 pprn), phase 4 (3400 * 100 pprn), and phase 1 
(3000 * 80 pprn). The four phases of hexane extracts contained lower amount of y- 
oryzanol than chloroform-methanol extracts. Phase 2 of rice milling contained the 
highest y-oryzanol content (4560 100 pprn), followed by phase 3 (2400 * 40 pprn),. 
phase 4 (2080 * 40 pprn), and phase 1 (1600 * 60 pprn). TAA studies showed that rice 
bran oil extracted from phase 2 of rice milling had significantly higher antioxidant 
activity than phase 1 (pc0.05). However, no significant differences were found among 
other phases (p0.05). It was found that rice bran is a good source of dietary fiber. 
However, fiber distribution was affected also by milling systems. Phase 2 of rice milling 
contained the highest amount of TDF which was 5 1.2 * 0.9 %, followed by phases 3, 1 
and 4 that contained 45.2 * 1.0 %, 37.6 * 0.1 % and 35.5 * 0.8 % respectively. 
Caco-2 cell line was used as in vitro model to study y-oryzanol bioavailability from 
different formulations that were triolein solution, emulsion, tocotrienol rich fraction 
(TRF)-y-oryzanol emulsion, and microspheres. By day 9, cell line showed polarized 
monolayer properties as was detected from transepithelial electrical resistance (TEER) 
value (247.2 * 25.0 &m2) and phenol red diffusion (4.2 + 0.1 %). However, all 
experiments were conducted at day 18, to ensure that cells were fully polarized. In vitro 
digestion of 100 mg dose from each formulation resulted in low micellarization 
concentrations of y-oryzanol from both triolein solution and microspheres, that were 2 1 
* 2 pglml digestate, and 20 * 2 pgml respectively. Nevertheless, micellarization 
concentrations were greatly improved to 5087 * 147 pglml and 5 160 + 228 pglml, from 
emulsion and TRF- y-oryzanol emulsion, respectively. After 10 h of incubation, only 
0.43 * 0.02 pg (2.03 +_ 0.09 %) y-oryzanol was transported to the lower compartments 
from triolein solution. Cellular uptake of y-oryzanol from microspheres after the same 
period of incubation, increased to 1.25 * 0.09 pg (6.33 f 0.44 %). Gamma oryzanol 
absorption increased further to 1 14.94 * 2.02 pg (2.3 1 f 0.04 %) and 1 15.82 * 4.52 pg 
(2.24 + 0.05 %) from emulsion and TRF- y-oryzanol emulsion, respectively. 
Phannacokinetics of y-oryzanol was studied using rabbits. Gamma oryzanol emulsion 
was given as a single intravenous dose. Plasma level of y-oryzanol was quantified using 
HPLC. Plasma clearance of y-oryzanol followed two compartments model, indicating 
that y-oryzanol was distributed to the internal tissues. Elimination constant was 0.086 * 
0.004 pg/ml.h, and the half-life was 8.040 * 0.360 h. 
Rabbits were used as in vivo model to study the bioavailability of y-oryzanol from 
triolein solution, microspheres, emulsion and TRF- y-oryzanol emulsion. The maximum 
concentration of y-oryzanol from triolein solution was 6.37 * 1.48 pg/ml, and improved 
to 130.30 * 30.40 pglml upon loading y-oryzanol in microspheres. However, in both 
formulations, the maximum concentrations were achieved after 2 h of ingestion. Where 
as the maximum concentrations of y-oryzanol from emulsion and TRF- y-oryzanol 
emulsion were 555 * 100 pglml and 525 * 95 pglml respectively and the t max. was 2 h. 
The absolute bioavailability of y-oryzanol emulsion was 6.61 * 0.86 %. The oral 
emulsion was used as a standard, so that the relative bioavailabilitiy (F relative) values 
of the other formulations were calculated. While F( relative) for y-oryzanol from triolein 
solution was only 0.51 * 0.06 %, it was significantly ('<0.05) increased to 16.63 * 1.71 
% upon loading y-oryzanol in microspheres. Addition of TRF to y-oryzanol emulsion 
resulted in an increase of F (relative) to 109.60 * 13.83 %. However, this increase could 
be due to the preservative effect of TRF antioxidants. 
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In conclusion, the bioavailability of y-oryzanol was low. However, its absorption 
increased around 200 times after emulsification and 33 times upon loading in 
microspheres. 
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Minyak dedak beras diekstrak daripada dedak beras yang diperolehi melalui empat 
peringkat proses pengilangan yang digunakan semasa memproses beras di kilang 
BERNAS, Sekinchan, Malaysia. Dua pelarut organik telah digunakan, pelarut bukan 
polar iaitu heksana dan pelarut campuran polar dan bukan polar iaitu kloroform-metanol. 
Kandungan gamma orizanol bagi minyak dedak beras telah ditentukan dan jumlah 
aktiviti antioksidan (JAA) telah ditentukan menggunakan kaedah FTC dan TBA. Selepas 
minyak diekstrak, kandungan fiber diet ditentukan dalam empat fasa dedak beras 
ternyahlemak. Hasil kajian menunjukkan dedak beras mengandungi lebih kurang 20 % 
lipid bagi kedua-dua pelarut yang digunakan. Berbeza dengan kandungan minyak, 
kepekatan orizanol dipengaruhi oleh fasa pengilangan dan jenis pelarut yang digunakan 
semasa pengekstrakan. Bagi ekstrak kloroform-metanol, fasa kedua proses pengilangan 
beras menunjukkan amaun y-orizanol yang tinggi (5280 f 120 ppm), diikuti fasa ketiga 
(3820 f 60 ppm), fasa keempat (3400 k 100 ppm) dan fasa pertama (3000 f 80 ppm). 
Keempat-empat fasa ekstrak heksana mengandungi peratus y-orizanol yang lebih rendah 
daripada ekstrak kloroform-metanol. Bagi ekstrak heksana, sarnpel daripada fasa kedua 
proses pengilangan beras menunjukkan peratusan y-orizanol yang tinggi (4560 f 100 
ppm), diikuti fasa ketiga (2400 f 40 ppm), fasa keempat (2080 f 40 ppm) dan fasa 
pertama (1600 f 60 ppm). Kajian menunjukkan JAA minyak dedak beras yang diekstrak 
daripada fasa kedua adalah lebih tinggi secara signifikan daripada fasa pertama (p<0.05). 
Narnun, tiada perbezaan yang signifikan (p>0.05) diperolehi antara fasa-fasa yang lain. 
Dedak beras merupakan sumber yang baik bagi fiber diet. Walau bagaimanapun taburan 
fiber turut dipengaruhi oleh sistem pengilangan. Fasa kedua bagi proses pengilangan 
beras mengandungi arnaun jumlah fiber diet (JFD) yang tinggi iaitu 5 1.2 f 0.9 %, diikuti 
fasa ketiga, fasa pertama dan fasa keempat yang mengandungi 45.2 f 1 .O %, 37.6 + 0.1 
% dan 35.5 f 0.8 % masing-masing. 
Sel Caco-2 digunakan sebagai model in vitro untuk mengkaji bioavailabiliti y-orizanol 
daripada formulasi yang berbeza, iaitu larutan triolein, emulsi yang kaya dengan 
pecahan tokotrienol dan mikrosfera. Semasa hari ke-9, titisan sel menunjukkan ciri-ciri 
ekalapis yang terpolar seperti yang nilai ditunjukkan oleh transepitelial rintangan 
elektrik (TEER) (247.2 f 25.0 !2cm2) dan difusi fen01 merah (0.42 f 0.08 %). Walau 
bagaimanapun, semua ujikaji yang dijalankan pada hari ke 18 menunjukkan sel-sel 
berpolar sepenuhnya. Pencernaan in vitro bagi dos 100 mg daripada setiap bentuk 
menunjukkan peratus pemiselan y-orizanol yang rendah bagi kedua-dua larutan triolein 
dan mikrosfera, iaitu 21 f 2 pg/ml dan 20 L- 2 pglml penghadaman masing-masing. 
Namun begitu, kepekatan pemiselan telah meningkat kepada 5087+ 147 pglml dan 5 160 
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k 228 pglml, daripada emulsi dan emulsi yang kaya pecahan tokotrienol masing-masing. 
Selepas 10 jam eraman, hanya 0.43 f 0.02 pg (2.03 f 0.09 %) y-orizanol diangkut 
kepada bahagian yang lebih rendah daripada larutan triolein. Pengambilan selular bagi 
orizanol daripada mikrosfera selepas tempoh eraman yang sama, meningkat kepada 1.25 
f 0.09 pg (6.33 f 0.44 %). Penyerapan y-orizanol semakin meningkat kepada 1 14.94 k 
2.02 pg (2.31 f 0.04 %) dan 115.82 f 4.52 pg (2.24 f 0.05 %) daripada emulsi dan 
emulsi yang kaya pecahan tokotrienol masing-masing. 
Farmakokinetik bagi y-orizanol dikaji dengan menggunakan arnab. Emulsi y-orizanol 
diberi sebagai dos intravena tunggal. Aras plasma bagi y-orizanol ditentukan dengan 
menggunakan HPLC. Pembersihan plasma y-orizanol mengikuti dua bahagian model, 
menunjukkan y-orizanol diagihkan kepada dua tisu dalaman. Pemalar penyingkiran ialah 
0.086 f 0.004 pg/ml.jam dan separuh hayat adalah 8.040 f 0.360 jam. 
Arnab digunakan sebagai model in vivo dalam kajian bioavailabiliti y-orizanol daripada 
larutan triolein, mikrosfera, emulsi dan fraksi kaya tokotrienol (FKT) dalam emulsi y- 
orizanol. Kepekatan maksimum y-orizanol daripada larutan triolein ialah 6.37 _+ 1.48 
pglml dan meningkat kepada 130.3 f 30.4 pglml setelah y-orizanol diberi dalam bentuk 
mikrosfera. Walau bagaimanapun, dalam kedua-dua bentuk, kepekatan maksimum 
dicapai selepas 2 jam penghadaman. Kepekatan maksimum y-orizanol daripada emulsi 
dan emulsi yang kaya pecahan tokotrienol pula ialah 555 f 100 pglml dan 525 f 95 
pglml masing-masing dan masa maksimum bagi kedua-dua bentuk ialah 2 jam. 
Bioavailabiliti bagi emulsi y-orizanol ialah 6.61 f 0.86 %. Emulsi secara oral digunakan 
sebagai piawaian, jadi nilai bioavailabiliti relatif (F relatif) bagi setiap bentuk dikira. F 
(relatif) bagi y-orizanol daripada larutan triolein hanya 0.51 + 0.06 %, tetapi ia 
meningkat secara signifikan (p<0.05) kepada 16.63 f 1.71 % apabila y-orizanol diberi 
dalam bentuk mikrosfera. Penambahan fraksi kaya tokotrienol (FKT) dalam emulsi 
orizanol menghasilkan peningkatan F (relatif) kepada 109.60 f 13.83 %. Walau 
bagaimanapun, peningkatan ini mungkin akibat daripada kesan pengawetan antioksidan 
FKT. 
Kesimpulannya, bioavailabiliti y-orizanol adalah rendah. Walau bagaimanapun, 
penyerapannya meningkat kira-kira 200 kali selepas emulsifikasi dan 33 kali selepas 
pemberian dalam bentuk mikrosfera. 
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CHAPTER 1 
INTRODUCTION 
Rice is a staple food for about 60 % of the world population. About 90 % of the 
world's rice is produced and consumed in Asia. It is second to wheat in terms of 
annual production. World rice production in 1991 was 466 million metric tonnes 
(Sayre, 1991), and it has been increasing faster than other grains. For example, by 
2002 it increased to 602 million metric tonnes (FAO, 2002). As a result of 
continuous growth in rice production and consumption, rice research and 
development activity has become important. 
In order to produce edible white rice, it is milled to produce hull, bran, germ, and the 
white rice. Rice hulls have no nutritional value, but rice bran and germ are rich in 
protein, lipids, vitamins, and trace minerals (Saunders, 1985). Currently the majority 
of rice bran is used as animal feed. The naturally occurring enzymatic activity of rice 
bran leads to the hydrolysis of the oil after milling. However, immediate stabilization 
of rice bran could convert it to a useful and a healthy product (Ramezanzadeh et al., 
1999). 
Due to its composition, nutritional profile, functional characteristics and 
hypoallergenicity, rice bran is added to provide a healthy diet, high in dietary fiber 
and low in saturated fat (Marshall and Wadsworth, 1994). In addition, Kahlon et al. 
(1990) found that rice bran was as effective as oat bran at lowering serum cholesterol 
in hypercholesterolemic hamsters. There are strong indications that the consumption 
of rice bran may be specifically beneficial in reducing the risk of cardiovascular 
disease, which is now the major cause of mortality in many countries (Marshall and 
Wadsworth, 1994; Khor, 1997). The mortality rate has been on the decline since 
1960s in countries such as Australia, New Zealand and Japan. However, in Malaysia 
and China mortality due to cardiovascular disease is increasing and reaching 30-40 
% in 1997 (Khor, 1997). Although it had been found that rice bran could protect 
from cardiovascular diseases, this effect was suggested mainly due to its antioxidants 
(Marshall and Wadsworth, 1994). 
Locally planted rice in Sekinchan is milled through two stage mills to remove first 
the hulls, and then the bran. However, bran is removed through four millers to 
produce four phases of rice bran. Few of previous research studied the milling 
conditions that affect the concentrations of rice bran antioxidants. Most studies 
focused on the extraction of rice bran oil and the isolation of its antioxidants. Others 
studied the health benefits of rice bran. Wells (1993) and Martin et al. (1993) studied 
the effect of heat or the stabilization process of rice bran on its tocopherols and 
-\ - 
tocotrienols levels. 
In comparison with other cereal brans, rice bran contains high oil content, which 
ranged from 16-32 % (Marshall and Wadsworth, 1994). In 1988, only 450,000 
metric tonnes of rice bran oil were produced in the world, despite the potential of 2 
million metric tonnes. Japan is the leading producer of rice bran oil with an average 
annual production of 100,000 metric tonnes (Sayre, 1988). Rice bran oil extraction 
began in Korea using the hydraulic press method. After that hexane extraction was 
carried out (Sayre, 1988). Supercritical fluid extraction is now investigated as 
alternative for organic extraction since organic solvents could be hazardous and 
expensive (Xu and Godber, 2000). 
Due to the low content of linolenic acid and high antioxidants content, including 
tocopherols, tocotrienols, y-oryzanol and phenolic compounds, rice bran oil has the 
ability to adjust cholesterol serum level (Marshall and Wadsworth, 1994). Rice bran 
oil contains 4.2 % of unsaponifiable matter, which is higher than any other common 
vegetable oils (Sayre, 1991). The unsaponifiable matter comprised mostly of sterols 
along with y-oryzanol. Crude rice bran oil can be refined to give a number of 
beneficial products, including edible rice bran oil, tocopherols and y-oryzanol. 
Gamma oryzanol is a mixture of ferulic acid esters of triterpene alcohols and plant 
sterols (Rogers et al., 1993). It had been found that crude rice bran oil contains 0.96- 
2.9 % y-oryzanol (Marshall and Wadsworth, 1994). Studies proved that y-oryzanol 
possesses curative functions for many human diseases, including a reduction of 
cholesterol level in human and inhibition of platelet aggregation (Seetharamaiah and 
Chandrasekhara, 1988; Cicero and Gaddi, 2001). In addition, it had been found that 
y-oryzanol had the ability to promote skin capillary circulation, and had anti-itching 
and anti-dandruff action, and has been used in cosmetics (Seetharamaiah and 
Prabhakar, 1986). However, plant sterols have limited bioavailability. As such, the 
benefits offered by y-oryzanol could be limited by its bioavailability. 
There are not many studies about the bioavailability and the pharmacokinetics of y- 
oryzanol. Fujiwara et al. (1983) determined the amount of radioactivity in rat's 
blood after the administration of radiolabelled y-oryzanol. The measurement of 
radioactivity in the blood could lead to overestimation of y-oryzanol since 
metabolites could also be detected. Fujiwara et al. (1983) reported that 10-20 % of 
